

Resource Summary Report

Generated by [NIF](#) on Sep 18, 2026

HEC-1-A

RRID:CVCL_0293

Type: Cell Line

Proper Citation

RRID:CVCL_0293

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0293

Proper Citation: RRID:CVCL_0293

Description: Cell line HEC-1-A is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Type II endometrial adenocarcinoma

Defining Citation: [PMID:327080](#), [PMID:833871](#), [PMID:2436984](#), [PMID:3410349](#), [PMID:3518877](#), [PMID:4678779](#), [PMID:7459858](#), [PMID:10381137](#), [PMID:12068308](#), [PMID:12227503](#), [PMID:12714694](#), [PMID:12893190](#), [PMID:15053063](#), [PMID:15901131](#), [PMID:20215515](#), [PMID:20218740](#), [PMID:22460905](#), [PMID:22710073](#), [PMID:25485619](#), [PMID:25984343](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#)

Comments: Population: Japanese., Part of: PI3K genetic alteration cell panel (ATCC TCP-1028)., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HEC-1-A

Synonyms: Hec-1-A, HEC-1A, HEC1-A, HEC1A, Hec1A

Cross References: BTO:BTO_0002960, CLO:CLO_0003674, EFO:EFO_0002191, MCCL:MCC:0000183, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ATCC:HTB-112, BCRC:60552, BioGRID_ORCS_Cell_line:421, BioSample:SAMN03471093, BioSample:SAMN03472456, BioSample:SAMN10988293, cancercellines:CVCL_0293, CCRID:3101HUMTCHu149,

Cell_Model_Passport:SIDM00595, ChEMBL-Cells:CHEMBL4295424, ChEMBL-Targets:CHEMBL4296424, CLS:305077, Cosmic:713474, Cosmic:713494, Cosmic:724853, Cosmic:809130, Cosmic:846177, Cosmic:871552, Cosmic:889115, Cosmic:1007160, Cosmic:1066222, Cosmic:1177620, Cosmic:1177685, Cosmic:1576457, Cosmic:1594188, Cosmic:1622896, Cosmic:2030464, Cosmic:2301550, Cosmic:2464665, Cosmic:2646619, DepMap:ACH-000954, EGA:EGAS00001000610, GEO:GSM844555, GEO:GSM844556, GEO:GSM887069, GEO:GSM888139, IARC_TP53:1110, IGRhCellID:HEC1A, JCRB:JCRB1117, JCRB:NIHS0388, LiGeA:CCLE_208, PharmacDB:HEC1A_524_2019, Progenetix:CVCL_0293, PubChem_Cell_line:CVCL_0293, Wikidata:Q54882246

ID: CVCL_0293

Hierarchy: cvcl_1274

Record Creation Time: 20220427T220324+0000

Record Last Update: 20260913T004003+0000

Ratings and Alerts

No rating or validation information has been found for HEC-1-A.

Warning: Discontinued: JCRB; NIHS0388

Population: Japanese., Part of: PI3K genetic alteration cell panel (ATCC TCP-1028)., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 398 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Huang TT, et al. (2026) DHX9 inhibition enhances paclitaxel sensitivity by inducing mitotic failure in ovarian and endometrial cancers. Molecular cancer therapeutics.

Peng J, et al. (2026) CBLC-mediated ubiquitination stabilizes METTL1, enhances N7-methylguanosine modification of ESRRA, and promotes the progression of endometrial cancer. International journal of biological macromolecules, 369, 152809.

Resch V, et al. (2026) Targeting Steroid-Metabolizing Enzymes with 15 β -Substituted Estrone Analogues: Dual Discovery of AKR1C2/17 β -HSD1 Inhibitors and a Fluorescent 17 β -HSD1 Ligand. Cancers, 18(12).

Santiappillai NT, et al. (2025) Pathway metabolite ratios reveal distinctive glutamine metabolism in a subset of proliferating cells. *Molecular systems biology*, 21(8), 983.

Nelson BE, et al. (2025) Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(18), 3864.

Yu H, et al. (2025) Assessment of NUDT5 in Endometrial Carcinoma: Functional Insights, Prognostic and Therapeutic Implications. *Biomedicines*, 13(5).

Lindén M, et al. (2025) FET fusion oncoproteins enrich SWI/SNF complex subtypes and interaction partners. *Cellular & molecular biology letters*, 30(1), 107.

Blinkiewicz PV, et al. (2025) Colorectal cancer-associated PCBP1 mutations disrupt protein stability in a dominant negative manner. *bioRxiv : the preprint server for biology*.

Aljardali MW, et al. (2024) Nucleolar Localization of the RNA Helicase DDX21 Predicts Survival Outcomes in Gynecologic Cancers. *Cancer research communications*, 4(6), 1495.

Dissanayake K, et al. (2024) Do extracellular vesicles have specific target cells?; Extracellular vesicle mediated embryo maternal communication. *Frontiers in molecular biosciences*, 11, 1415909.

Gjorgoska M, et al. (2024) Pre-receptor regulation of 11-oxyandrogens differs between normal and cancerous endometrium and across endometrial cancer grades and molecular subtypes. *Frontiers in endocrinology*, 15, 1404804.

Meril S, et al. (2024) Loss of EIF4G2 mediates aggressiveness in distinct human endometrial cancer subpopulations with poor survival outcome in patients. *Oncogene*.

Joseph R, et al. (2024) EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer. *International journal of molecular sciences*, 25(2).

Okumura T, et al. (2024) Rel Family Transcription Factor NFAT5 Upregulates COX2 via HIF-1? Activity in Ishikawa and HEC1a Cells. *International journal of molecular sciences*, 25(7).

Tang S, et al. (2023) ERR? Up-Regulates Invadopodia Formation by Targeting HMGCS1 to Promote Endometrial Cancer Invasion and Metastasis. *International journal of molecular sciences*, 24(4).

Su Y, et al. (2023) Ubiquitin-specific peptidase 14 maintains estrogen receptor ? stability via its deubiquitination activity in endometrial cancer. *The Journal of biological chemistry*, 299(1), 102734.

Zhao X, et al. (2023) Effects of RFRP?3 on an ovariectomized estrogen?primed rat model and HEC?1A human endometrial carcinoma cells. *Experimental and therapeutic medicine*, 25(2), 76.

Ruan GY, et al. (2023) An integrated approach of network pharmacology, molecular docking, and experimental verification uncovers kaempferol as the effective modulator of HSD17B1 for treatment of endometrial cancer. *Journal of translational medicine*, 21(1), 204.

Niu L, et al. (2023) Identification and validation of oxeiptosis-associated lncRNAs and prognosis-related signature genes to predict the immune status in uterine corpus endometrial carcinoma. *Aging*, 15(10), 4236.

Pandur E, et al. (2023) The Role of Fractalkine in the Regulation of Endometrial Iron Metabolism in Iron Deficiency. *International journal of molecular sciences*, 24(12).